Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (8)
- Hematology (5)
- Oncology (5)
- Life Sciences (4)
- Diseases (3)
-
- Bioinformatics (2)
- Biomedical Informatics (2)
- Cancer Biology (2)
- Cardiology (2)
- Cell and Developmental Biology (2)
- Hemic and Lymphatic Diseases (2)
- Medical Sciences (2)
- Pediatrics (2)
- Civic and Community Engagement (1)
- Education (1)
- Infectious Disease (1)
- Liberal Studies (1)
- Public Health (1)
- Public Health Education and Promotion (1)
- Social and Behavioral Sciences (1)
- Sociology (1)
- Virus Diseases (1)
- Institution
- Publication
- Publication Type
Articles 1 - 11 of 11
Full-Text Articles in Medicine and Health Sciences
Antihuman T Lymphocyte Porcine Immunoglobulin Combined With Cyclosporine As First-Line Immunosuppressive Therapy For Severe Aplastic Anemia In China: A Large Single-Center, 10-Year Retrospective Study, Wenrui Yang, Xu Liu, Xin Zhao, Li Zhang, Guangxin Peng, Lei Ye, Kang Zhou, Yuan Li, Jianping Li, Huihui Fan, Yang Yang, Youzhen Xiong, Liping Jing, Fengkui Zhang
Antihuman T Lymphocyte Porcine Immunoglobulin Combined With Cyclosporine As First-Line Immunosuppressive Therapy For Severe Aplastic Anemia In China: A Large Single-Center, 10-Year Retrospective Study, Wenrui Yang, Xu Liu, Xin Zhao, Li Zhang, Guangxin Peng, Lei Ye, Kang Zhou, Yuan Li, Jianping Li, Huihui Fan, Yang Yang, Youzhen Xiong, Liping Jing, Fengkui Zhang
Student and Faculty Publications
BACKGROUND: Antihuman T lymphocyte porcine immunoglobulin (p-ATG) has been the most common ATG preparation in immunosuppressive therapy (IST) in Chinese patients with severe aplastic anemia (SAA) since 2009.
OBJECTIVES: This study aimed to evaluate the early hematologic response and long-term outcomes of a large cohort of patients with SAA who received p-ATG plus cyclosporine (CsA) as first-line therapy from 2010 to 2019.
DESIGN: This is a single-center retrospective study of medical records.
METHODS: We analyzed the data of 1023 consecutive patients with acquired aplastic anemia (AA) who underwent p-ATG combined with CsA as a first-line IST treatment from 2010 to …
Efficacy Of Eltrombopag With Immunosuppressive Therapy For Children With Acquired Aplastic Anemia, Yufei Zhao, Wenrui Yang, Xin Zhao, Xiangrong Hu, Jing Hu, Xu Liu, Jianping Li, Lei Ye, Youzhen Xiong, Yang Yang, Baohang Zhang, Xiaoxia Li, Xiawan Yang, Yimeng Shi, Guangxin Peng, Yuan Li, Huihui Fan, Kang Zhou, Liping Jing, Li Zhang, Fengkui Zhang
Efficacy Of Eltrombopag With Immunosuppressive Therapy For Children With Acquired Aplastic Anemia, Yufei Zhao, Wenrui Yang, Xin Zhao, Xiangrong Hu, Jing Hu, Xu Liu, Jianping Li, Lei Ye, Youzhen Xiong, Yang Yang, Baohang Zhang, Xiaoxia Li, Xiawan Yang, Yimeng Shi, Guangxin Peng, Yuan Li, Huihui Fan, Kang Zhou, Liping Jing, Li Zhang, Fengkui Zhang
Student and Faculty Publications
BACKGROUND: Eltrombopag (EPAG), an oral thrombopoietin receptor agonist (TPO-RA), has been proven to improve the hematologic response without increasing toxic effects as a first-line therapy combined with standard immunosuppressive treatment (IST) in adults with severe aplastic anemia (SAA). Nevertheless, the clinical evidence on the efficacy of EPAG in children with acquired aplastic anemia is limited and controversial.
METHODS: We performed a single-center, retrospective study to analyze the clinical outcomes of fifteen patients aged ≤18 years with newly diagnosed acquired SAA who received first-line IST and EPAG (EPAG group) compared with those of forty-five patients who received IST alone (IST group) …
Hepatitis-Associated Aplastic Anemia, Alfadel Alshaibani, Carlo Dufour, Antonio Risitano, Regis De Latour, Mahmoud Aljurf
Hepatitis-Associated Aplastic Anemia, Alfadel Alshaibani, Carlo Dufour, Antonio Risitano, Regis De Latour, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Hepatitis-associated aplastic anemia (HAAA) is a rare illness, characterized by onset of pancytopenia with a hypoplastic bone marrow that traditionally occurs within 6 months of an increase in serum aminotransferases. HAAA is observed in 1% to 5% of all newly diagnosed cases of acquired aplastic anemia. Several hepatitis viruses have been linked to the disease, but in many cases no specific virus is detected. The exact pathophysiology is unknown; however, immune destruction of hematopoietic stem cells is believed to be the underlying mechanism. HAAA is a potentially lethal disease if left untreated. Management includes immunosuppression with antithymocyte globulin and cyclosporine …
Outcome Of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As A Treatment Option In Patients With Severe Aplastic Anemia Between 40 And 50 Years, Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Outcome Of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation As A Treatment Option In Patients With Severe Aplastic Anemia Between 40 And 50 Years, Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Hematology/Oncology and Stem Cell Therapy
The frontline treatment for patients younger than 40 years with severe aplastic anemia (AA) is allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-identical sibling donor. However, in patients with severe AA who are older than 40 years, allogeneic HSCT has been found to be associated with increased treatment related mortality and toxicity, even when matched sibling donors are used. We report our institutional experience with allogeneic HSCT in patients with severe AA between 40 and 50 years. A total of 19 patients with severe AA were included in the study. Overall survival (OS) and disease-free survival (DFS) …
Case Report: Tocilizumab For The Treatment Of Sars-Cov-2 Infection In A Patient With Aplastic Anemia, Gina Keiffer, Zach French, Lindsay Wilde, Joanne Filicko-O'Hara, Usama Gergis, Adam Binder
Case Report: Tocilizumab For The Treatment Of Sars-Cov-2 Infection In A Patient With Aplastic Anemia, Gina Keiffer, Zach French, Lindsay Wilde, Joanne Filicko-O'Hara, Usama Gergis, Adam Binder
Department of Medicine Faculty Papers
While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment …
Bone Marrow Drive: Will Linfield Be The Match?, Ashley Filler
Bone Marrow Drive: Will Linfield Be The Match?, Ashley Filler
Student Engagement Posters
Ashley Filler discusses student engagement at Linfield College with regard to organizing a bone marrow registration drive.
Aplastic Anemia In Hiv-Infected Persons, S Insiripong, W Yingsitsiri, J Boondumrongsagul, J. Noiwattanakul
Aplastic Anemia In Hiv-Infected Persons, S Insiripong, W Yingsitsiri, J Boondumrongsagul, J. Noiwattanakul
Chulalongkorn Medical Journal
No abstract provided.
Clopidogrel Hypersensitivity: Clinical Challenges And Options For Management., Kimberly L Campbell, John R Cohn, Michael P Savage
Clopidogrel Hypersensitivity: Clinical Challenges And Options For Management., Kimberly L Campbell, John R Cohn, Michael P Savage
Michael P Savage M.D.
Over 90 million patients have been prescribed clopidogrel since its US FDA approval in 1997. Clopidogrel hypersensitivity affects up to 6% of patients, most commonly in the form of a pruritic rash. Symptoms are severe enough to result in drug discontinuation in 1.5% of patients. Premature discontinuation of clopidogrel is problematic following percutaneous coronary intervention because of the risk of stent thrombosis leading to myocardial infarction and death. Accordingly, the management of patients with clopidogrel hypersensitivity is of significant clinical importance. Conventional clopidogrel desensitization protocols, while successful in most patients, employ a washout period off medication to enable accurate detection …
Clopidogrel Hypersensitivity: Clinical Challenges And Options For Management., Kimberly L Campbell, John R Cohn, Michael P Savage
Clopidogrel Hypersensitivity: Clinical Challenges And Options For Management., Kimberly L Campbell, John R Cohn, Michael P Savage
Division of Cardiology Faculty Papers
Over 90 million patients have been prescribed clopidogrel since its US FDA approval in 1997. Clopidogrel hypersensitivity affects up to 6% of patients, most commonly in the form of a pruritic rash. Symptoms are severe enough to result in drug discontinuation in 1.5% of patients. Premature discontinuation of clopidogrel is problematic following percutaneous coronary intervention because of the risk of stent thrombosis leading to myocardial infarction and death. Accordingly, the management of patients with clopidogrel hypersensitivity is of significant clinical importance. Conventional clopidogrel desensitization protocols, while successful in most patients, employ a washout period off medication to enable accurate detection …
Increased Risk For Aplastic Anemia And Myelodysplastic Syndrome In Individuals Lacking Glutathione S-Transferase Genes, Joanne F. Sutton, Michael Stacey, William G. Kearns, Thomas S. Roeg, Neal S. Young, Johnson M. Liu
Increased Risk For Aplastic Anemia And Myelodysplastic Syndrome In Individuals Lacking Glutathione S-Transferase Genes, Joanne F. Sutton, Michael Stacey, William G. Kearns, Thomas S. Roeg, Neal S. Young, Johnson M. Liu
Bioelectrics Publications
BACKGROUND: Aplastic anemia (AA) and myelodysplastic syndrome (MDS) are marrow failure states that may be associated with chromosomal instability. An absence of the glutathione S-transferase (GST) enzyme may genetically predispose individuals to AA or MDS. PROCEDURE AND RESULTS: To test this hypothesis, we determined the GSTM1 and GSTT1 genotypes in a total of 196 patients using multiplex PCR. The GSTT1 null genotype was found to be overrepresented in Caucasian, Asian, and Hispanic patients with either AA or MDS. We confirmed a difference in the expected frequency of the GSTM1 null genotype in Caucasian MDS patients. The double null GSTM1/GSTT1 …
Successful Allogeneic Bone Marrow Transplantation (Bmt) Following Orthotopic Liver Transplantation (Olt) For Fulminant Hepatic Failure And Severe Aplastic Anemia (Saa) Due To Non A Non B Non C Hepatitis., Darrell J. White, Thomas J. Nevill, Vivian C. Mcalister
Successful Allogeneic Bone Marrow Transplantation (Bmt) Following Orthotopic Liver Transplantation (Olt) For Fulminant Hepatic Failure And Severe Aplastic Anemia (Saa) Due To Non A Non B Non C Hepatitis., Darrell J. White, Thomas J. Nevill, Vivian C. Mcalister
Vivian C. McAlister
No abstract provided.